Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.

about

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.

Item

http://www.wikidata.org/entity/Q54977480

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Inhibiting Janus Kinase 1 and ...... eukemia with IL7-Rα mutations.

@en

Inhibiting Janus Kinase 1 and ...... eukemia with IL7-Rα mutations.

@nl

type

Item

label

Inhibiting Janus Kinase 1 and ...... eukemia with IL7-Rα mutations.

@en

Inhibiting Janus Kinase 1 and ...... eukemia with IL7-Rα mutations.

@nl

prefLabel

Inhibiting Janus Kinase 1 and ...... eukemia with IL7-Rα mutations.

@en

Inhibiting Janus Kinase 1 and ...... eukemia with IL7-Rα mutations.

@nl

P1476

Inhibiting Janus Kinase 1 and ...... eukemia with IL7-Rα mutations.

@en

P2093

Caroline Andrews

http://www.w3.org/2001/XMLSchema#string

Emilee Senkevitch

http://www.w3.org/2001/XMLSchema#string

Gary T Pauly

http://www.w3.org/2001/XMLSchema#string

Julie A Hixon

http://www.w3.org/2001/XMLSchema#string

Kelli Czarra

http://www.w3.org/2001/XMLSchema#string

Sarah D Cramer

http://www.w3.org/2001/XMLSchema#string

Scott K Durum

http://www.w3.org/2001/XMLSchema#string

Timothy Back

http://www.w3.org/2001/XMLSchema#string

Wenqing Li

http://www.w3.org/2001/XMLSchema#string

P2860

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

The biology of pediatric acute megakaryoblastic leukemia

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

P304

22605-22617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25194

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29854301

http://www.w3.org/2001/XMLSchema#string

P932

5978251

http://www.w3.org/2001/XMLSchema#string